You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTipranavir
Accession NumberDB00932  (APRD01306)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. It is administered with ritonavir in combination therapy to treat HIV infections.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aptivussolution100 mg/mLoralBoehringer Ingelheim Pharmaceuticals, Inc.2008-09-01Not applicableUs
Aptivuscapsule, liquid filled250 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2005-07-01Not applicableUs
Aptivuscapsule250 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2005-12-01Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tipranavir disodium
191150-83-1
Thumb
  • InChI Key: ZBWMQTUSVWBMQE-KPHXKKTMSA-M
  • Monoisotopic Mass: 646.17011633
  • Average Mass: 646.63
DBSALT001882
Categories
UNIIZZT404XD09
CAS number174484-41-4
WeightAverage: 602.664
Monoisotopic: 602.206227481
Chemical FormulaC31H33F3N2O5S
InChI KeySUJUHGSWHZTSEU-FYBSXPHGSA-N
InChI
InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1
IUPAC Name
N-{3-[(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulfonamide
SMILES
[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as linear diarylheptanoids. These are diarylheptanoids with an open heptane chain. The two aromatic rings are linked only by the heptane chain.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassDiarylheptanoids
Sub ClassLinear diarylheptanoids
Direct ParentLinear diarylheptanoids
Alternative Parents
Substituents
  • Linear 1,7-diphenylheptane skeleton
  • Sulfanilide
  • Pyridine-2-sulfonamide
  • Phenylpropane
  • Dihydropyranone
  • Benzenoid
  • Pyridine
  • Pyran
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous acid
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Lactone
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Enol
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
PharmacodynamicsTipranavir is a non-peptidic protease inhibitor (PI) of HIV. Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Mechanism of actionTipranavir (TPV) is a non-peptidic HIV-1 protease inhibitor that inhibits the processing of the viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions. Two mechanisms are suggested in regards to the potency of tipranavir: 1. Tipravanir may bind to the active site of the protease enzyme with fewer hydrogen bonds than peptidic protease inhibitors, which results in increased flexibility, allowing it to fit into the active site of the enzyme in viruses that have become resistance to other protease inhibitors. This also enables tipranavir to adjust to amino acid substitutions at the active site. 2. Tipranavir's strong hydrogen bonding interaction with the amide backbone of the protease active site Asp30 may lead to its activity against resistant viruses.
Related Articles
AbsorptionAbsorption is limited, although no absolute quantification of absorption is available.
Volume of distributionNot Available
Protein bindingExtensive (> 99.9%), to both human serum albumin and α-1-acid glycoprotein.
Metabolism

Hepatic. In vitro metabolism studies with human liver microsomes indicated that CYP 3A4 is the predominant CYP enzyme involved in tipranavir metabolism.

Route of eliminationNot Available
Half life5-6 hours
ClearanceNot Available
ToxicityOral LD50 in rat is over 5,000 mg/kg. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.
Affected organisms
  • Human Immunodeficiency Virus
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9066
Blood Brain Barrier-0.6801
Caco-2 permeable-0.6103
P-glycoprotein substrateSubstrate0.5277
P-glycoprotein inhibitor INon-inhibitor0.5057
P-glycoprotein inhibitor IINon-inhibitor0.9249
Renal organic cation transporterNon-inhibitor0.9277
CYP450 2C9 substrateNon-substrate0.8364
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5143
CYP450 1A2 substrateNon-inhibitor0.6708
CYP450 2C9 inhibitorNon-inhibitor0.5711
CYP450 2D6 inhibitorNon-inhibitor0.8485
CYP450 2C19 inhibitorNon-inhibitor0.5383
CYP450 3A4 inhibitorNon-inhibitor0.5442
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5317
Ames testNon AMES toxic0.6078
CarcinogenicityNon-carcinogens0.728
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5773 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8277
hERG inhibition (predictor II)Non-inhibitor0.702
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral250 mg
Capsule, liquid filledoral250 mg/1
Solutionoral100 mg/mL
Prices
Unit descriptionCostUnit
Aptivus 120 250 mg capsule Bottle1271.8USD bottle
Aptivus 250 mg capsule10.19USD capsule
Aptivus 100 mg/ml solution4.29USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2187523 No2006-11-212015-05-04Canada
CA2294033 No2007-01-092018-07-27Canada
US5852195 Yes1999-12-222019-12-22Us
US6147095 Yes2000-04-292020-04-29Us
US6169181 No1994-05-062014-05-06Us
US6231887 Yes1999-01-272019-01-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
logP6.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000205 mg/mLALOGPS
logP6.29ALOGPS
logP7.14ChemAxon
logS-6.5ALOGPS
pKa (Strongest Acidic)5.92ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area105.59 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity154.57 m3·mol-1ChemAxon
Polarizability60.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Franz Klingler, “Enantioselective hydrogenation of intermediates in the synthesis of tipranavir.” U.S. Patent US20040224990, issued November 11, 2004.

US20040224990
General References
  1. Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG: Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res. 2005 Oct;68(1):27-35. [PubMed:16122817 ]
  2. Authors unspecified: Tipranavir: PNU 140690, tipranivir. Drugs R D. 2006;7(1):55-62. [PubMed:16620137 ]
  3. Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7. [PubMed:17712762 ]
  4. Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18. [PubMed:18158073 ]
External Links
ATC CodesJ05AE09
AHFS Codes
  • 08:18.08.08
PDB EntriesNot Available
FDA labelDownload (388 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Tipranavir.
3,4-DichloroisocoumarinThe serum concentration of 3,4-Dichloroisocoumarin can be decreased when it is combined with Tipranavir.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE can be decreased when it is combined with Tipranavir.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Tipranavir.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Tipranavir.
AbciximabTipranavir may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Tipranavir can be decreased when combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Tipranavir.
AcenocoumarolTipranavir may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Tipranavir.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Tipranavir.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Tipranavir.
Acetylsalicylic acidTipranavir may increase the antiplatelet activities of Acetylsalicylic acid.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Tipranavir.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Tipranavir.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Tipranavir.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Tipranavir.
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Tipranavir.
Alpha-1-proteinase inhibitorThe serum concentration of Alpha-1-proteinase inhibitor can be decreased when it is combined with Tipranavir.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Tipranavir.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Tipranavir.
AlprostadilTipranavir may increase the antiplatelet activities of Alprostadil.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Tipranavir.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Tipranavir.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Tipranavir.
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Tipranavir.
AmiodaroneThe metabolism of Tipranavir can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Tipranavir.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Tipranavir.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Tipranavir.
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Tipranavir.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Tipranavir.
AnagrelideTipranavir may increase the antiplatelet activities of Anagrelide.
AncrodTipranavir may increase the anticoagulant activities of Ancrod.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Tipranavir.
Antithrombin III humanThe serum concentration of Antithrombin III human can be decreased when it is combined with Tipranavir.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Tipranavir.
AprepitantThe serum concentration of Tipranavir can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Tipranavir.
AprotininThe serum concentration of Aprotinin can be decreased when it is combined with Tipranavir.
ArdeparinTipranavir may increase the anticoagulant activities of Ardeparin.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Tipranavir.
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Tipranavir.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Tipranavir.
ArmodafinilThe metabolism of Tipranavir can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Tipranavir can be decreased when combined with Artemether.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Tipranavir.
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Tipranavir.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Tipranavir.
AtazanavirThe metabolism of Tipranavir can be decreased when combined with Atazanavir.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Tipranavir.
AtomoxetineThe metabolism of Tipranavir can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Tipranavir.
AzelastineTipranavir may increase the antiplatelet activities of Azelastine.
BatimastatThe serum concentration of Batimastat can be decreased when it is combined with Tipranavir.
BazedoxifeneBazedoxifene may increase the dermatologic adverse activities of Tipranavir.
BecaplerminTipranavir may increase the anticoagulant activities of Becaplermin.
BenazeprilThe serum concentration of Benazepril can be decreased when it is combined with Tipranavir.
BenzamidineThe serum concentration of Benzamidine can be decreased when it is combined with Tipranavir.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Tipranavir.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Tipranavir.
BepridilThe serum concentration of Bepridil can be increased when it is combined with Tipranavir.
BeraprostTipranavir may increase the antiplatelet activities of Beraprost.
BetaxololThe metabolism of Tipranavir can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Tipranavir can be decreased when it is combined with Bexarotene.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Tipranavir.
BivalirudinThe serum concentration of Bivalirudin can be decreased when it is combined with Tipranavir.
BoceprevirThe serum concentration of Tipranavir can be decreased when it is combined with Boceprevir.
BortezomibThe metabolism of Tipranavir can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Tipranavir can be decreased when it is combined with Bosentan.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Tipranavir.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Tipranavir.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Tipranavir.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Tipranavir.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Tipranavir.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Tipranavir.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Tipranavir.
BupropionThe metabolism of Bupropion can be decreased when combined with Tipranavir.
BuspironeThe metabolism of Buspirone can be decreased when combined with Tipranavir.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Tipranavir.
CaffeineThe metabolism of Caffeine can be decreased when combined with Tipranavir.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tipranavir.
CandoxatrilThe serum concentration of Candoxatril can be decreased when it is combined with Tipranavir.
CangrelorTipranavir may increase the antiplatelet activities of Cangrelor.
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Tipranavir.
CarbamazepineThe metabolism of Tipranavir can be increased when combined with Carbamazepine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Tipranavir.
CarteololThe metabolism of Carteolol can be decreased when combined with Tipranavir.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Tipranavir.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Tipranavir.
CelecoxibThe metabolism of Tipranavir can be decreased when combined with Celecoxib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Tipranavir.
CeritinibThe serum concentration of Tipranavir can be increased when it is combined with Ceritinib.
CertoparinTipranavir may increase the anticoagulant activities of Certoparin.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Tipranavir.
ChloramphenicolThe metabolism of Tipranavir can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Tipranavir.
ChloroquineThe metabolism of Tipranavir can be decreased when combined with Chloroquine.
ChlorotrianiseneChlorotrianisene may increase the dermatologic adverse activities of Tipranavir.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Tipranavir.
ChlorpromazineThe metabolism of Tipranavir can be decreased when combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tipranavir.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Tipranavir.
CholecalciferolThe metabolism of Tipranavir can be decreased when combined with Cholecalciferol.
ChymostatinThe serum concentration of Chymostatin can be decreased when it is combined with Tipranavir.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Tipranavir.
CilastatinThe serum concentration of Cilastatin can be decreased when it is combined with Tipranavir.
CilazaprilThe serum concentration of Cilazapril can be decreased when it is combined with Tipranavir.
CilostazolTipranavir may increase the antiplatelet activities of Cilostazol.
CimetidineThe metabolism of Tipranavir can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Tipranavir can be decreased when combined with Cinacalcet.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Tipranavir.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Tipranavir.
CitalopramThe metabolism of Tipranavir can be decreased when combined with Citalopram.
Citric AcidTipranavir may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Tipranavir.
ClarithromycinThe metabolism of Tipranavir can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Tipranavir can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Tipranavir.
ClobazamThe metabolism of Tipranavir can be decreased when combined with Clobazam.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Tipranavir.
ClomipramineThe metabolism of Tipranavir can be decreased when combined with Clomipramine.
ClonidineThe metabolism of Clonidine can be decreased when combined with Tipranavir.
ClopidogrelTipranavir may increase the antiplatelet activities of Clopidogrel.
ClotrimazoleThe metabolism of Tipranavir can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Tipranavir can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Tipranavir can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Tipranavir can be decreased when combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Tipranavir.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Tipranavir.
ConivaptanThe serum concentration of Tipranavir can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensConjugated Equine Estrogens may increase the dermatologic adverse activities of Tipranavir.
CrizotinibThe metabolism of Tipranavir can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Tipranavir.
CyclophosphamideThe risk or severity of adverse effects can be increased when Tipranavir is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Tipranavir.
CyclosporineThe metabolism of Tipranavir can be decreased when combined with Cyclosporine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Tipranavir.
DabrafenibThe serum concentration of Tipranavir can be decreased when it is combined with Dabrafenib.
DalteparinTipranavir may increase the anticoagulant activities of Dalteparin.
DanaparoidTipranavir may increase the anticoagulant activities of Danaparoid.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Tipranavir.
DarifenacinThe metabolism of Tipranavir can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Tipranavir can be increased when it is combined with Darunavir.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Tipranavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Tipranavir.
DasatinibThe serum concentration of Tipranavir can be increased when it is combined with Dasatinib.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Tipranavir.
DeferasiroxThe serum concentration of Tipranavir can be decreased when it is combined with Deferasirox.
DefibrotideTipranavir may increase the antiplatelet activities of Defibrotide.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Tipranavir.
DelavirdineThe metabolism of Tipranavir can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Tipranavir.
DesipramineThe metabolism of Tipranavir can be decreased when combined with Desipramine.
DesirudinTipranavir may increase the anticoagulant activities of Desirudin.
DexamethasoneThe serum concentration of Tipranavir can be decreased when it is combined with Dexamethasone.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Tipranavir.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Tipranavir.
DextranTipranavir may increase the anticoagulant activities of Dextran.
Dextran 40Tipranavir may increase the anticoagulant activities of Dextran 40.
Dextran 70Tipranavir may increase the anticoagulant activities of Dextran 70.
Dextran 75Tipranavir may increase the anticoagulant activities of Dextran 75.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Tipranavir.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Tipranavir.
DicoumarolTipranavir may increase the anticoagulant activities of Dicoumarol.
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Tipranavir.
DienestrolDienestrol may increase the dermatologic adverse activities of Tipranavir.
DiethylstilbestrolDiethylstilbestrol may increase the dermatologic adverse activities of Tipranavir.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tipranavir.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Tipranavir.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Tipranavir.
DihydroergotamineThe metabolism of Tipranavir can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Tipranavir can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Tipranavir can be decreased when combined with Diphenhydramine.
DipyridamoleTipranavir may increase the antiplatelet activities of Dipyridamole.
DisulfiramThe risk or severity of adverse effects can be increased when Disulfiram is combined with Tipranavir.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Tipranavir.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Tipranavir.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Tipranavir.
DonepezilThe metabolism of Donepezil can be decreased when combined with Tipranavir.
DopamineThe metabolism of Dopamine can be decreased when combined with Tipranavir.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Tipranavir.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Tipranavir.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Tipranavir.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Tipranavir.
DoxycyclineThe metabolism of Tipranavir can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Tipranavir can be decreased when combined with Dronedarone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Tipranavir.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Tipranavir.
DuloxetineThe metabolism of Tipranavir can be decreased when combined with Duloxetine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Tipranavir.
EcabetThe serum concentration of Ecabet can be decreased when it is combined with Tipranavir.
Edetic AcidTipranavir may increase the anticoagulant activities of Edetic Acid.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Tipranavir.
EfavirenzThe serum concentration of Tipranavir can be decreased when it is combined with Efavirenz.
ElafinThe serum concentration of Elafin can be decreased when it is combined with Tipranavir.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Tipranavir.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Tipranavir.
EliglustatThe metabolism of Tipranavir can be decreased when combined with Eliglustat.
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Tipranavir.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tipranavir.
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Tipranavir.
EnalaprilatThe serum concentration of Enalaprilat can be decreased when it is combined with Tipranavir.
EnalkirenThe serum concentration of Enalkiren can be decreased when it is combined with Tipranavir.
EncainideThe metabolism of Encainide can be decreased when combined with Tipranavir.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Tipranavir.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Tipranavir.
EnoxaparinTipranavir may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Tipranavir can be decreased when it is combined with Enzalutamide.
EpinastineTipranavir may increase the antiplatelet activities of Epinastine.
EpoprostenolTipranavir may increase the antiplatelet activities of Epoprostenol.
EptifibatideTipranavir may increase the antiplatelet activities of Eptifibatide.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Tipranavir.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Tipranavir.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Tipranavir.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Tipranavir.
ErythromycinThe metabolism of Tipranavir can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Tipranavir.
Eslicarbazepine acetateThe serum concentration of Tipranavir can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Tipranavir.
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Tipranavir.
EsomeprazoleThe metabolism of Tipranavir can be decreased when combined with Esomeprazole.
EstradiolEstradiol may increase the dermatologic adverse activities of Tipranavir.
EstriolEstriol may increase the dermatologic adverse activities of Tipranavir.
EstroneEstrone may increase the dermatologic adverse activities of Tipranavir.
Ethinyl EstradiolEthinyl Estradiol may increase the dermatologic adverse activities of Tipranavir.
Ethyl biscoumacetateTipranavir may increase the anticoagulant activities of Ethyl biscoumacetate.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Tipranavir.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Tipranavir.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Tipranavir.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Tipranavir.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tipranavir.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Tipranavir.
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Tipranavir.
FluconazoleThe metabolism of Tipranavir can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Tipranavir.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Tipranavir.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Tipranavir.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Tipranavir.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Tipranavir.
FluvoxamineThe metabolism of Tipranavir can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumTipranavir may increase the anticoagulant activities of Fondaparinux sodium.
FormoterolThe metabolism of Formoterol can be decreased when combined with Tipranavir.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Tipranavir.
FosamprenavirThe metabolism of Tipranavir can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Tipranavir can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Tipranavir.
FosphenytoinThe serum concentration of Tipranavir can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Tipranavir can be increased when it is combined with Fusidic Acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Tipranavir.
GarlicThe serum concentration of Tipranavir can be decreased when it is combined with Garlic.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Tipranavir.
GeldanamycinThe serum concentration of Geldanamycin can be decreased when it is combined with Tipranavir.
GemfibrozilThe metabolism of Tipranavir can be decreased when combined with Gemfibrozil.
GenisteinGenistein may increase the dermatologic adverse activities of Tipranavir.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Tipranavir.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Tipranavir.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Tipranavir.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Tipranavir.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Tipranavir.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Tipranavir.
GM6001The serum concentration of GM6001 can be decreased when it is combined with Tipranavir.
GranisetronThe metabolism of Granisetron can be decreased when combined with Tipranavir.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Tipranavir.
HaloperidolThe metabolism of Tipranavir can be decreased when combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Tipranavir.
HeparinTipranavir may increase the anticoagulant activities of Heparin.
HexestrolHexestrol may increase the dermatologic adverse activities of Tipranavir.
HirulogThe serum concentration of Hirulog can be decreased when it is combined with Tipranavir.
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Tipranavir resulting in a loss in efficacy.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Tipranavir.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Tipranavir.
IbudilastTipranavir may increase the antiplatelet activities of Ibudilast.
Icosapent ethylTipranavir may increase the antiplatelet activities of Icosapent ethyl.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Tipranavir.
IdelalisibThe serum concentration of Tipranavir can be increased when it is combined with Idelalisib.
IfenprodilTipranavir may increase the antiplatelet activities of Ifenprodil.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Tipranavir.
IloprostTipranavir may increase the antiplatelet activities of Iloprost.
ImatinibThe metabolism of Tipranavir can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Tipranavir.
ImipramineThe metabolism of Tipranavir can be decreased when combined with Imipramine.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Tipranavir.
IndinavirThe metabolism of Tipranavir can be decreased when combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Tipranavir.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Tipranavir.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Tipranavir.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Tipranavir.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tipranavir.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Tipranavir.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Tipranavir.
IsavuconazoniumThe metabolism of Tipranavir can be decreased when combined with Isavuconazonium.
IsoflurophateThe serum concentration of Isoflurophate can be decreased when it is combined with Tipranavir.
IsoniazidThe metabolism of Tipranavir can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Tipranavir can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Tipranavir.
ItraconazoleThe metabolism of Tipranavir can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Tipranavir can be increased when it is combined with Ivacaftor.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Tipranavir.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Tipranavir.
KetoconazoleThe metabolism of Tipranavir can be decreased when combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Tipranavir.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Tipranavir.
LepirudinThe serum concentration of Lepirudin can be decreased when it is combined with Tipranavir.
LevodopaThe metabolism of Levodopa can be decreased when combined with Tipranavir.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Tipranavir.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Tipranavir.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Tipranavir.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Tipranavir.
LisinoprilThe serum concentration of Lisinopril can be decreased when it is combined with Tipranavir.
LisurideThe metabolism of Lisuride can be decreased when combined with Tipranavir.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Tipranavir.
LomustineThe metabolism of Lomustine can be decreased when combined with Tipranavir.
LoperamideThe metabolism of Loperamide can be decreased when combined with Tipranavir.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Tipranavir.
LopinavirThe metabolism of Tipranavir can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Tipranavir.
LorcaserinThe metabolism of Tipranavir can be decreased when combined with Lorcaserin.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Tipranavir.
LovastatinThe metabolism of Tipranavir can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Tipranavir can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Tipranavir can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Tipranavir can be decreased when combined with Lumefantrine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Tipranavir.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Tipranavir.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Tipranavir.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Tipranavir.
MestranolMestranol may increase the dermatologic adverse activities of Tipranavir.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Tipranavir.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Tipranavir.
MethadoneThe metabolism of Tipranavir can be decreased when combined with Methadone.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Tipranavir.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Tipranavir.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Tipranavir.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Tipranavir.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Tipranavir.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Tipranavir.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Tipranavir.
MetoprololThe metabolism of Tipranavir can be decreased when combined with Metoprolol.
MetronidazoleThe risk or severity of adverse effects can be increased when Metronidazole is combined with Tipranavir.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Tipranavir.
MianserinThe metabolism of Mianserin can be decreased when combined with Tipranavir.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Tipranavir.
MifepristoneThe metabolism of Tipranavir can be decreased when combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Tipranavir.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Tipranavir.
MilrinoneTipranavir may increase the antiplatelet activities of Milrinone.
MinaprineThe metabolism of Minaprine can be decreased when combined with Tipranavir.
MirabegronThe metabolism of Tipranavir can be decreased when combined with Mirabegron.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Tipranavir.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Tipranavir.
MitotaneThe serum concentration of Tipranavir can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Tipranavir.
ModafinilThe serum concentration of Tipranavir can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Moexipril can be decreased when it is combined with Tipranavir.
MorphineThe metabolism of Morphine can be decreased when combined with Tipranavir.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline can be decreased when it is combined with Tipranavir.
NadroparinTipranavir may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Tipranavir can be decreased when it is combined with Nafcillin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Tipranavir.
NCX 4016The serum concentration of NCX 4016 can be decreased when it is combined with Tipranavir.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Tipranavir.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Tipranavir.
NefazodoneThe metabolism of Tipranavir can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Tipranavir.
NelfinavirThe metabolism of Tipranavir can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Tipranavir can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Tipranavir.
NevirapineThe metabolism of Tipranavir can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Tipranavir can be decreased when combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Tipranavir.
NicotineThe metabolism of Nicotine can be decreased when combined with Tipranavir.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Tipranavir.
NilotinibThe metabolism of Tipranavir can be decreased when combined with Nilotinib.
NimesulideTipranavir may increase the antiplatelet activities of Nimesulide.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Tipranavir.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Tipranavir.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Tipranavir.
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Tipranavir.
OlaparibThe metabolism of Tipranavir can be decreased when combined with Olaparib.
OmapatrilatThe serum concentration of Omapatrilat can be decreased when it is combined with Tipranavir.
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Tipranavir.
OmeprazoleThe metabolism of Tipranavir can be decreased when combined with Omeprazole.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Tipranavir.
OsimertinibThe serum concentration of Tipranavir can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Otamixaban can be decreased when it is combined with Tipranavir.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Tipranavir.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Tipranavir.
PalbociclibThe serum concentration of Tipranavir can be increased when it is combined with Palbociclib.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Tipranavir.
PanobinostatThe metabolism of Tipranavir can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Tipranavir.
PantoprazoleThe metabolism of Tipranavir can be decreased when combined with Pantoprazole.
ParoxetineThe metabolism of Tipranavir can be decreased when combined with Paroxetine.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Tipranavir.
Peginterferon alfa-2bThe serum concentration of Tipranavir can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Tipranavir.
PentobarbitalThe metabolism of Tipranavir can be increased when combined with Pentobarbital.
Pentosan PolysulfateTipranavir may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllineTipranavir may increase the antiplatelet activities of Pentoxifylline.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Tipranavir.
PerindoprilThe serum concentration of Perindopril can be decreased when it is combined with Tipranavir.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Tipranavir.
PethidineThe risk or severity of adverse effects can be increased when Tipranavir is combined with Pethidine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Tipranavir.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Tipranavir.
PhenindioneTipranavir may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Tipranavir can be decreased when it is combined with Phenobarbital.
PhenprocoumonTipranavir may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Tipranavir can be decreased when it is combined with Phenytoin.
PhosphoramidonThe serum concentration of Phosphoramidon can be decreased when it is combined with Tipranavir.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Tipranavir.
PindololThe metabolism of Pindolol can be decreased when combined with Tipranavir.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Tipranavir.
PiperazineThe metabolism of Piperazine can be decreased when combined with Tipranavir.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Tipranavir.
Polyestradiol phosphatePolyestradiol phosphate may increase the dermatologic adverse activities of Tipranavir.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Tipranavir.
PosaconazoleThe metabolism of Tipranavir can be decreased when combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Tipranavir.
PrasugrelTipranavir may increase the antiplatelet activities of Prasugrel.
PrimidoneThe metabolism of Tipranavir can be increased when combined with Primidone.
PrinomastatThe serum concentration of Prinomastat can be decreased when it is combined with Tipranavir.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Tipranavir.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Tipranavir.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Tipranavir.
PromazineThe metabolism of Tipranavir can be decreased when combined with Promazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Tipranavir.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Tipranavir.
PropofolThe metabolism of Propofol can be decreased when combined with Tipranavir.
PropranololThe metabolism of Propranolol can be decreased when combined with Tipranavir.
Protein CTipranavir may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeTipranavir may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Tipranavir.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Tipranavir.
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Tipranavir.
QuinaprilThe serum concentration of Quinapril can be decreased when it is combined with Tipranavir.
QuinestrolQuinestrol may increase the dermatologic adverse activities of Tipranavir.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Tipranavir.
QuinidineThe metabolism of Tipranavir can be decreased when combined with Quinidine.
QuinineThe metabolism of Tipranavir can be decreased when combined with Quinine.
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Tipranavir.
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Tipranavir.
RamiprilThe serum concentration of Ramipril can be decreased when it is combined with Tipranavir.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Tipranavir.
RanolazineThe metabolism of Tipranavir can be decreased when combined with Ranolazine.
RemikirenThe serum concentration of Remikiren can be decreased when it is combined with Tipranavir.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Tipranavir.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Tipranavir.
repinotanThe metabolism of repinotan can be decreased when combined with Tipranavir.
ResveratrolTipranavir may increase the antiplatelet activities of Resveratrol.
ReviparinTipranavir may increase the anticoagulant activities of Reviparin.
RidogrelTipranavir may increase the antiplatelet activities of Ridogrel.
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Tipranavir.
RifabutinThe metabolism of Tipranavir can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Tipranavir can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Tipranavir can be increased when combined with Rifapentine.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Tipranavir.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Tipranavir.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Tipranavir.
RitonavirThe metabolism of Tipranavir can be decreased when combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Tipranavir.
RolapitantThe metabolism of Tipranavir can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Tipranavir can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Tipranavir.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Tipranavir.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Tipranavir.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Tipranavir.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Tipranavir.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Tipranavir.
SaquinavirThe metabolism of Tipranavir can be decreased when combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Tipranavir.
SCH-530348Tipranavir may increase the antiplatelet activities of SCH-530348.
SertindoleThe metabolism of Sertindole can be decreased when combined with Tipranavir.
SertralineThe metabolism of Tipranavir can be decreased when combined with Sertraline.
SevofluraneTipranavir may increase the antiplatelet activities of Sevoflurane.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Tipranavir.
SildenafilThe metabolism of Tipranavir can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Tipranavir can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Tipranavir can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Tipranavir.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Tipranavir.
SparteineThe metabolism of Sparteine can be decreased when combined with Tipranavir.
SpiraprilThe serum concentration of Spirapril can be decreased when it is combined with Tipranavir.
SRT501Tipranavir may increase the antiplatelet activities of SRT501.
St. John's WortThe metabolism of Tipranavir can be increased when combined with St. John's Wort.
StiripentolThe serum concentration of Tipranavir can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Tipranavir can be decreased when combined with Sulfisoxazole.
SulodexideTipranavir may increase the anticoagulant activities of Sulodexide.
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may increase the dermatologic adverse activities of Tipranavir.
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may increase the dermatologic adverse activities of Tipranavir.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Tipranavir.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Tipranavir.
TAK-390MRThe serum concentration of TAK-390MR can be decreased when it is combined with Tipranavir.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Tipranavir resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Tipranavir.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Tipranavir.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Tipranavir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Tipranavir.
TelaprevirThe metabolism of Tipranavir can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Tipranavir can be decreased when combined with Telithromycin.
TemocaprilThe serum concentration of Temocapril can be decreased when it is combined with Tipranavir.
TemsirolimusThe risk or severity of adverse effects can be increased when Tipranavir is combined with Temsirolimus.
TenofovirThe serum concentration of Tipranavir can be decreased when it is combined with Tenofovir.
TerbinafineThe metabolism of Tipranavir can be decreased when combined with Terbinafine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Tipranavir.
TesmilifeneTipranavir may increase the antiplatelet activities of Tesmilifene.
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Tipranavir.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Tipranavir.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tipranavir.
ThioridazineThe metabolism of Tipranavir can be decreased when combined with Thioridazine.
ThiorphanThe serum concentration of Thiorphan can be decreased when it is combined with Tipranavir.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Tipranavir.
TiboloneTibolone may increase the dermatologic adverse activities of Tipranavir.
TiclopidineTipranavir may increase the antiplatelet activities of Ticlopidine.
TiclopidineThe metabolism of Tipranavir can be decreased when combined with Ticlopidine.
TimololThe metabolism of Timolol can be decreased when combined with Tipranavir.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Tipranavir.
TirofibanTipranavir may increase the antiplatelet activities of Tirofiban.
TocilizumabThe serum concentration of Tipranavir can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Tipranavir.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tipranavir.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Tipranavir.
TopiramateThe metabolism of Tipranavir can be decreased when combined with Topiramate.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Tipranavir.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Tipranavir.
TrandolaprilThe serum concentration of Trandolapril can be decreased when it is combined with Tipranavir.
TranilastTipranavir may increase the antiplatelet activities of Tranilast.
TranylcypromineThe metabolism of Tipranavir can be decreased when combined with Tranylcypromine.
TrapidilTipranavir may increase the antiplatelet activities of Trapidil.
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Tipranavir.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Tipranavir.
TriflusalTipranavir may increase the antiplatelet activities of Triflusal.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Tipranavir.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Tipranavir.
UbenimexThe serum concentration of Ubenimex can be decreased when it is combined with Tipranavir.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Tipranavir.
VenlafaxineThe metabolism of Tipranavir can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Tipranavir can be decreased when combined with Verapamil.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Tipranavir.
VildagliptinThe serum concentration of Vildagliptin can be decreased when it is combined with Tipranavir.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Tipranavir.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Tipranavir.
Vitamin EThe risk or severity of adverse effects can be increased when Tipranavir is combined with Vitamin E.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Tipranavir.
VorapaxarTipranavir may increase the antiplatelet activities of Vorapaxar.
VoriconazoleThe metabolism of Tipranavir can be decreased when combined with Voriconazole.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Tipranavir.
WarfarinTipranavir may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Ximelagatran can be decreased when it is combined with Tipranavir.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Tipranavir.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Tipranavir.
ZeranolZeranol may increase the dermatologic adverse activities of Tipranavir.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Tipranavir.
ZiprasidoneThe metabolism of Tipranavir can be decreased when combined with Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Tipranavir.
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Tipranavir.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Aspartic-type endopeptidase activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72874
Molecular Weight:
10778.7 Da
References
  1. Koh Y, Matsumi S, Das D, Amano M, Davis DA, Li J, Leschenko S, Baldridge A, Shioda T, Yarchoan R, Ghosh AK, Mitsuya H: Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem. 2007 Sep 28;282(39):28709-20. Epub 2007 Jul 17. [PubMed:17635930 ]
  2. Tenore SB, Ferreira PR: The Place of protease inhibitors in antiretroviral treatment. Braz J Infect Dis. 2009 Oct;13(5):371-4. doi: 10.1590/S1413-86702009000500012. [PubMed:20428639 ]
  3. Muzammil S, Armstrong AA, Kang LW, Jakalian A, Bonneau PR, Schmelmer V, Amzel LM, Freire E: Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations. J Virol. 2007 May;81(10):5144-54. Epub 2007 Mar 14. [PubMed:17360759 ]
  4. Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC: Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure. BMC Infect Dis. 2009 Sep 14;9:154. doi: 10.1186/1471-2334-9-154. [PubMed:19751502 ]
  5. Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7. [PubMed:17712762 ]
  6. Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18. [PubMed:18158073 ]
  7. Croom KF, Keam SJ: Tipranavir: a ritonavir-boosted protease inhibitor. Drugs. 2005;65(12):1669-77; discussion 1678-9. [PubMed:16060700 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7. [PubMed:17712762 ]
  2. Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18. [PubMed:18158073 ]
  3. Li F, Wang L, Guo GL, Ma X: Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8. doi: 10.1124/dmd.109.030817. Epub 2010 Jan 26. [PubMed:20103582 ]
  4. Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD: A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42. doi: 10.1038/clpt.2009.253. Epub 2010 Feb 10. [PubMed:20147896 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Li F, Wang L, Guo GL, Ma X: Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8. doi: 10.1124/dmd.109.030817. Epub 2010 Jan 26. [PubMed:20103582 ]
  2. Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD: A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42. doi: 10.1038/clpt.2009.253. Epub 2010 Feb 10. [PubMed:20147896 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Li F, Wang L, Guo GL, Ma X: Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8. doi: 10.1124/dmd.109.030817. Epub 2010 Jan 26. [PubMed:20103582 ]
  2. Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD: A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42. doi: 10.1038/clpt.2009.253. Epub 2010 Feb 10. [PubMed:20147896 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 03:28